Longeveron finishes enrollment in stem cell trial for Alzheimer’s disease

Longeveron said today that it finished enrollment for the 1st phase of its human mesenchymal stem cell trial for Alzheimer’s disease.

The company enrolled and infused 5 patients to collect safety data for its exogenously administered mesenchymal stem cells derived from adult donors’ bone marrow.

Get the full story at our sister site, Drug Delivery Business News.

The post Longeveron finishes enrollment in stem cell trial for Alzheimer’s disease appeared first on MassDevice.

from MassDevice http://ift.tt/2mz3xpc